Pharmaceutical

Emalex eyes FDA approval for Tourette syndrome therapy after Phase III success

The Phase III trial met the primary and secondary endpoints of reducing tics in children and adult patients with Tourette syndrome.

Feb 27, 2025 - 06:00
Emalex eyes FDA approval for Tourette syndrome therapy after Phase III success
The Phase III trial met the primary and secondary endpoints of reducing tics in children and adult patients with Tourette syndrome.
Read the original article

Tags:

Previous Article

Eikon raises almost $351m to advance cancer candidates through the clinic

Next Article

Idorsia’s Tryvio deal collapses, forcing company to find cash urgently

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH

STAT+: Obesity treatment from Boehringer Ingelheim, Zea...

Feb 27, 2024

STAT+: Akero’s treatment for NASH falls short in cirrhosis study

STAT+: Akero’s treatment for NASH falls short in cirrho...

Oct 10, 2023

Panbela obtains rights to develop and commercialise Flynpovi to treat FAP

Panbela obtains rights to develop and commercialise Fly...

Apr 12, 2023